AGTX (Agentix) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 26, 2026)


What is Agentix Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Agentix's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

AGTX vs CERO, EVFM, EMMA: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, Agentix's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Agentix Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Agentix's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Agentix's Margin of Safety % (DCF FCF Based) falls into.


Agentix Business Description

Address 32932 Pacific Coast Highway, No. 14-254, Dana Point, CA, USA, 92629
Agentix Corp is a biotechnology company. Through its subsidiary, it is engaged in the development and commercialization of novel therapeutics to treat metabolic diseases, peripheral neuropathy, progressive lung disease, and ischemic reperfusion injury. Its principal business objective is to develop both science-driven synthetic and natural cannabinoid therapeutics that address unmet medical needs and continue to drive innovations in the endocannabinoid space. Its pipeline of drug candidates includes AGTX-2004, a CB1 receptor antagonist that has demonstrated efficacy in animal models of obesity and type 2 diabetes mellitus (T2DM), and AGTX-2003 a peripherally-acting CB1 receptor inverse agonist that has demonstrated efficacy in animal models of obesity and non-alcoholic fatty liver disease.